Post-Marketing Surveillance of Synagis in Korean Pediatric Patients Under the "New Drug Re-Examination"
Phase of Trial: Phase IV
Latest Information Update: 15 Jul 2015
At a glance
- Drugs Palivizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors Abbott Laboratories; AbbVie
- 26 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 01 Mar 2012 New trial record